Ribon Therapeutics is a clinical stage biopharmaceutical company based in Cambridge, MA, dedicated to developing innovative small molecule therapeutics that target stress support pathways in cancer and inflammation. Their proprietary BEACON platform enables the discovery and development of novel drugs by unlocking the biochemical roles of NAD-utilizing enzymes.
With a focus on developing potent and selective inhibitors, Ribon Therapeutics is advancing their lead product candidate, RBN-2397, as a promising treatment for solid tumors. Through their pioneering approach, Ribon Therapeutics aims to revolutionize the field of therapeutics by targeting stress support pathways and addressing unmet medical needs.
Generated from the website